AU2022405685A1 - Treatment of nociceptive pain - Google Patents

Treatment of nociceptive pain Download PDF

Info

Publication number
AU2022405685A1
AU2022405685A1 AU2022405685A AU2022405685A AU2022405685A1 AU 2022405685 A1 AU2022405685 A1 AU 2022405685A1 AU 2022405685 A AU2022405685 A AU 2022405685A AU 2022405685 A AU2022405685 A AU 2022405685A AU 2022405685 A1 AU2022405685 A1 AU 2022405685A1
Authority
AU
Australia
Prior art keywords
pain
polypeptide
seq
meteorin
sequence
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
AU2022405685A
Other languages
English (en)
Inventor
Torsten MELDGAARD MADSEN
Gordon Munro
Kenneth Petersen
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Hoba Therapeutics Aps
Original Assignee
Hoba Therapeutics Aps
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoba Therapeutics Aps filed Critical Hoba Therapeutics Aps
Publication of AU2022405685A1 publication Critical patent/AU2022405685A1/en
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4702—Regulators; Modulating activity
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pain & Pain Management (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Rheumatology (AREA)
  • Toxicology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
AU2022405685A 2021-12-10 2022-12-08 Treatment of nociceptive pain Pending AU2022405685A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP21213798.8 2021-12-10
EP21213798 2021-12-10
PCT/EP2022/084971 WO2023104960A1 (en) 2021-12-10 2022-12-08 Treatment of nociceptive pain

Publications (1)

Publication Number Publication Date
AU2022405685A1 true AU2022405685A1 (en) 2024-07-11

Family

ID=78829708

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2022405685A Pending AU2022405685A1 (en) 2021-12-10 2022-12-08 Treatment of nociceptive pain

Country Status (8)

Country Link
US (1) US20250325627A1 (enExample)
EP (1) EP4444338A1 (enExample)
JP (1) JP2024546758A (enExample)
KR (1) KR20240118796A (enExample)
CN (1) CN118488846A (enExample)
AU (1) AU2022405685A1 (enExample)
CA (1) CA3239550A1 (enExample)
WO (1) WO2023104960A1 (enExample)

Family Cites Families (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4352883A (en) 1979-03-28 1982-10-05 Damon Corporation Encapsulation of biological material
US4353888A (en) 1980-12-23 1982-10-12 Sefton Michael V Encapsulation of live animal cells
US4407957A (en) 1981-03-13 1983-10-04 Damon Corporation Reversible microencapsulation of a core material
US5169637A (en) 1983-03-24 1992-12-08 The Liposome Company, Inc. Stable plurilamellar vesicles
CA1237671A (en) 1983-08-01 1988-06-07 Michael W. Fountain Enhancement of pharmaceutical activity
US4762915A (en) 1985-01-18 1988-08-09 Liposome Technology, Inc. Protein-liposome conjugates
IL79289A (en) 1985-07-05 1992-01-15 Whitehead Biomedical Inst Introduction and expression of foreign genetic material into keratinocytes using a recombinant retrovirus
US4883666A (en) 1987-04-29 1989-11-28 Massachusetts Institute Of Technology Controlled drug delivery system for treatment of neural disorders
ATE117375T1 (de) 1987-09-11 1995-02-15 Whitehead Biomedical Inst Transduktionsveränderte fibroblasten und ihre anwendung.
US5082670A (en) 1988-12-15 1992-01-21 The Regents Of The University Of California Method of grafting genetically modified cells to treat defects, disease or damage or the central nervous system
US5185154A (en) 1989-02-02 1993-02-09 Liposome Technology, Inc. Method for instant preparation of a drug containing large unilamellar vesicles
US5399346A (en) 1989-06-14 1995-03-21 The United States Of America As Represented By The Department Of Health And Human Services Gene therapy
US5084350A (en) 1990-02-16 1992-01-28 The Royal Institution For The Advance Of Learning (Mcgill University) Method for encapsulating biologically active material including cells
US5618531A (en) 1990-10-19 1997-04-08 New York University Method for increasing the viability of cells which are administered to the brain or spinal cord
US5219990A (en) 1991-01-28 1993-06-15 Biogen, Inc. Papillomavirus e2 trans-activation repressors
ATE156344T1 (de) 1991-04-25 1997-08-15 Univ Brown Res Found Implantierbare, biokompatible immunisolator- trägersubstanz zum abgeben ausgesuchter, therapeutischer produkte
CA2150803C (en) 1992-12-02 2006-01-31 Henry Auer Controlled release growth hormone containing microspheres
EP0804249A2 (en) 1994-03-15 1997-11-05 Brown University Research Foundation Polymeric gene delivery system
US5656465A (en) 1994-05-04 1997-08-12 Therion Biologics Corporation Methods of in vivo gene delivery
PT779806E (pt) 1994-09-09 2001-02-28 Takeda Chemical Industries Ltd Preparacao de libertacao sustentada contendo um sal metalico de um peptido
PT831787E (pt) 1995-06-07 2002-02-28 Alkermes Inc Composicao para libertacao sustentada da hormona de crescimento humano
US5677158A (en) 1995-06-07 1997-10-14 Research Foundation Of State University Of New York In vitro packaging of adeno-associated virus DNA
ZA965368B (en) 1995-07-14 1997-01-14 Novo Nordisk As A pharmaceutical formulation
US6683058B1 (en) 1998-04-15 2004-01-27 Regents Of The University Of California Methods for therapy of neurodegenerative disease of the brain
WO1999061066A2 (en) 1998-05-27 1999-12-02 Avigen, Inc. Convection-enhanced delivery of aav vectors
US6361771B1 (en) 1999-04-06 2002-03-26 Neurotech S.A. ARPE-19 as a platform cell line for encapsulated cell-based delivery
US20020037281A1 (en) 2000-05-26 2002-03-28 Davidson Beverly L. Methods of transducing neural cells using lentivirus vectors
US6555674B2 (en) 2000-08-09 2003-04-29 Nsgene A/S JeT promoter
CN1525866B (zh) 2001-03-28 2013-05-29 比奥根艾迪克Ma公司 神经胚活素多肽的治疗作用
AU2005229434B2 (en) 2004-03-30 2010-09-30 Nsgene A/S Therapeutic use of a growth factor, NsG33
TWI501774B (zh) 2006-02-27 2015-10-01 Biogen Idec Inc 神經性病症之治療
WO2012041328A1 (en) 2010-10-01 2012-04-05 Nsgene A/S Use of meteorin for the treatment of allodynia, hyperalgesia, spontaneous pain and phantom pain
JP6145667B2 (ja) * 2011-09-05 2017-06-14 ホーバ セラピューティクス アンパルトセルスカブ アロディニア、痛覚過敏、自発痛、及び幻痛の治療

Also Published As

Publication number Publication date
JP2024546758A (ja) 2024-12-26
CA3239550A1 (en) 2023-06-15
CN118488846A (zh) 2024-08-13
KR20240118796A (ko) 2024-08-05
EP4444338A1 (en) 2024-10-16
WO2023104960A1 (en) 2023-06-15
US20250325627A1 (en) 2025-10-23

Similar Documents

Publication Publication Date Title
US9314502B2 (en) Treatment of allodynia, hyperalgesia, spontaneous pain and phantom pain
EP2753347B1 (en) Treatment of allodynia, hyperalgsia, spontaneous pain, and phantom pain
US20150353626A1 (en) Apolipoprotein a-i derived peptides for treatment of hyperglycaemia
US20250325627A1 (en) Treatment of nociceptive pain
US20240218033A1 (en) Prevention and treatment of chemotherapy-induced neuropathic pain
US20090136552A1 (en) Growth factors nsg28, nsg30, and nsg32
HK1186412B (en) Use of meteorin for the treatment of allodynia, hyperalgesia, spontaneous pain and phantom pain
US20090087474A1 (en) Therapeutic use of growth factors,nsg29 and nsg31
HK1199395B (en) Treatment of allodynia, hyperalgsia, spontaneous pain, and phantom pain